SCHEMBL6065210

SCHEMBL6065210

CCOC(=O)C(F)(F)C(O)CCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
THRB P10828 1/20 0.50
ALDH1A1 P00352 1/20 0.46
RECQL P46063 1/20 0.46
MMP8 P22894 1/20 0.46
POLB P06746 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
LMNA P02545 1/20 0.44
PIN1 Q13526 1/20 0.44
MAPT P10636 2/20 0.43
TDP1 Q9NUW8 2/20 0.42
PRSS1 P07477 2/20 0.42
CTSG P08311 2/20 0.42
CTRB1 P17538 2/20 0.42
CMA1 P23946 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7339469 0.84 METAP2 (0.43) TDP1PRSS1CTSGCTRB1CMA1
SCHEMBL22739330 0.81 TDP1 (0.45) TAAR1THRBALDH1A1RECQLMMP8
SCHEMBL7268813 0.81 CES1 (0.44) SMN1; SMN2POLBTDP1TSHR
SCHEMBL30800927 0.79 ALDH1A1 (0.39) TAAR1SMN1; SMN2ALDH1A1RECQLPOLB
SCHEMBL12482713 0.77 MMP8 (0.35) THRBALDH1A1MMP8POLBNPSR1
SCHEMBL2008727 0.77 TAAR1 (0.53) TAAR1SMN1; SMN2THRBALDH1A1RECQL
SCHEMBL1143435 0.77 POLB (0.48) TAAR1THRBALDH1A1RECQLMMP8
SCHEMBL614649 0.76 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1MMP8POLBLMNA
SCHEMBL991355 0.76 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1MMP8POLBLMNA
SCHEMBL820513 0.76 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1MMP8POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084281-B2 Synthesis of dihalohydrins and tri- and tetra-substituted olefins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-08-01 US disclosed
US-20040143125-A1 Synthesis of dihalohydrins and tri- and tetra-substituted olefins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2004-07-22 US disclosed
EP-0839798-A2 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-05-06 EP disclosed
US-5670675-A Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1997-09-23 US disclosed
US-5545750-A TREATING HUMAN IMMUNODEFICIENCY VIRUS ABBOTT LABORATORIES (US) 1996-08-13 US disclosed
US-5142056-A Human immunodeficiency virus protease inhibitor ABBOTT LABORATORIES (US) 1992-08-25 US disclosed
EP-0402646-A1 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1990-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040143125-A1 Synthesis of dihalohydrins and tri- and tetra-substituted olefins TALDO1, HDHD5, TKT TAAR1 1495/4885SMN1; SMN2 4691/4885THRB 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.